In:
International Journal of Cancer, Wiley, Vol. 142, No. 12 ( 2018-06-15), p. 2567-2577
Abstract:
What's new? Capecitabine is effective against breast, colorectal and gastric cancers and can be orally administered, making it an appealing therapeutic option. Its use, however, can be limited by the development of hand‐foot syndrome (HFS), a common side effect that negatively impacts quality of life. The effectiveness of HFS prevention strategies is unclear. The authors of this study evaluated previously reported prevention and treatment strategies for capecitabine‐induced HFS. Celecoxib was associated with reduced occurrence of grade 2 or higher HFS, while pyridoxine did not significantly improve HFS symptoms and topical urea/lactic acid was found to be ineffective in preventing the condition.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8